Steatohepatitis
| Steatohepatitis | |
|---|---|
| Specialty | Gastroenterology  |
Steatohepatitis (not to be confused with hepatic steatosis, or Non-alcoholic fatty liver disease/ fatty liver disease) is a type of liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver (steato-, meaning "fat", hepatitis, meaning "inflammation of the liver"). More deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes. [medical citation needed]
Classically seen in alcoholics as part of alcoholic liver disease, steatohepatitis is also frequently found in people with diabetes and obesity and is related to metabolic syndrome. When not associated with excessive alcohol intake, it is referred to as nonalcoholic steatohepatitis (NASH), and is the progressive form of the relatively benign non-alcoholic fatty liver disease.[1] Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.[medical citation needed]
Alcoholic steatohepatitis
Chronic alcohol intake commonly causes steatohepatitis.[medical citation needed]
Non-alcoholic steatohepatitis (NASH)
Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol. No pharmacological treatment has received approval as of 2015 for NASH.[2] Some studies suggest diet, exercise, and antiglycemic drugs may alter the course of the disease. General recommendations include improving metabolic risk factors and reducing alcohol intake.[3][4] NASH was first described in 1980 in a series of patients of the Mayo Clinic.[5] Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes.[6]
See also
References
- ^ Vuppalanchi R, Chalasani N (January 2009). "Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management". Hepatology. 49 (1): 306–17. doi:10.1002/hep.22603. PMC 2766096. PMID 19065650.
- ^ Ratziu, V; Goodman, Z; Sanyal, A (April 2015). "Current efforts and trends in the treatment of NASH". Journal of hepatology. 62 (1 Suppl): S65-75. doi:10.1016/j.jhep.2015.02.041. PMID 25920092.
- ^ Adams LA, Angulo P (2006). "Treatment of non-alcoholic fatty liver disease". Postgrad Med J. 82 (967): 315–22. doi:10.1136/pgmj.2005.042200. PMC 2563793. PMID 16679470.
- ^ Veena J, Muragundla A, Sidgiddi S, Subramaniam S (2014). "Non-alcoholic fatty liver disease: need for a balanced nutritional source". Br. J. Nutr. 112 (11): 1858–72. doi:10.1017/S0007114514002591. PMID 25274101.
- ^ Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980). "Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease". Mayo Clin Proc. 55 (7): 434–438. PMID 7382552.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Cassiman D, Jaeken J (2008). "NASH may be trash". Gut. 57 (2): 141–4. doi:10.1136/gut.2007.123240. PMID 18192446.
External links
- Hepatitis C Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
NASHBIOTECHS An overview of NASH disease and future treatments